Please login to the form below

Not currently logged in
Email:
Password:

Aragon Pharma

This page shows the latest Aragon Pharma news and features for those working in and with pharma, biotech and healthcare.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.

Latest news

  • J&J completes Aragon deal as Seragon is born J&J completes Aragon deal as Seragon is born

    The deal secures a promising new prostate cancer therapy for the pharma major in the form of Aragon's ARN-509, a second generation androgen receptor signalling inhibitor which has reached ... Seragon spun out. The closure of the deal also sees the

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...